Tumor Intrinsic Pathways

Tumor Intrinsic Pathways are a treatment paradigm that consider the molecular and cellular features of a tumor to enable the development of tailor-made therapeutic approaches for individual patients that are ultimately more effective. With our research, we are aiming at disrupting the intracellular tumor signaling pathways responsible for the development and survival of cancer.


For example, non-small cell lung cancers (NSCLC) carry a mutation in exon 20 of the epidermal growth factor receptor (EGFR) gene and is associated with poor prognosis. These mutations cannot be addressed with traditional EGFR inhibitors.


Derived from a long-standing alliance with the Broad Institute of MIT and Harvard, we have an early asset which targets this mutation in the EGFR.


The Bayer Research Innovation Centre (BRIC) in Boston-Cambridge, Massachusetts, U.S., is home to the company’s precision molecular oncology laboratory and reflects the investment Bayer is making to advance the future of oncology and science to generate breakthrough solutions to the world’s most complex challenges.